Baker Brothers Affiliate Files Intent to Sell $220K in Protara Therapeutics Shares Amid Coordinated Disposition

summarizeSummary

667, L.P., an affiliate of Baker Brothers Life Sciences, has filed a Form 144 indicating its intent to sell 35,173 shares of Protara Therapeutics common stock, valued at approximately $220,151. This is part of a larger, coordinated disposition by the institutional investor group.

check_boxKey Events

• Intent to Sell Shares

  667, L.P., an affiliate of Baker Brothers Life Sciences, intends to sell 35,173 shares of Protara Therapeutics common stock.

• Significant Transaction Value

  The proposed sale is valued at approximately $220,151.

• Part of Coordinated Disposition

  This sale is explicitly linked to a larger, coordinated disposition by the Baker Brothers group, totaling 459,298 shares across related filings.

• Institutional Investor Selling

  The filer is a "Former Affiliate" of Baker Brothers Life Sciences, indicating a reduction in their investment.

auto_awesomeAnalysis

This Form 144 filing from 667, L.P., an affiliate of Baker Brothers Life Sciences, signals a continued reduction in their stake in Protara Therapeutics. While the proposed sale of 35,173 shares (valued at approximately $220,151) is modest on its own, the filing explicitly states it's part of a larger, coordinated disposition by the institutional group totaling 459,298 shares across related filings. This ongoing selling pressure from a significant former affiliate could create an overhang on the stock, especially following recent positive clinical trial results which might have provided a liquidity window for the investor. Investors should monitor further filings from this group for signs of a complete exit or continued selling pressure.